Molecular evidence for the role of inflammation in dry eye disease.

Clin Exp Optom

Department of Ophthalmology, New Zealand National Eye Centre, The University of Auckland, Auckland, New Zealand.

Published: September 2019

Ocular surface inflammation is propagated by a complex series of molecular processes and has been implicated in the pathogenesis of dry eye disease (DED), either as a causal or a downstream effect of ocular surface disease. A state of hyperosmolarity elicits an acute immune response in DED, leading to subsequent activation of the adaptive immune response. This cascade incites dysregulation of the immune system, triggering a vicious cycle of events that causes damage to the ocular surface. Symptoms associated with these events include burning, irritation, redness, photophobia and blurred vision. The chronic nature of the disease process can cause permanent alterations to the ocular surface and adnexa. An increasing investment in treatment options, and positive outcomes with novel therapies that have received subsequent regulatory approval, lends further support to the role of inflammation in DED. This review highlights the nature and function of a range of fundamental inflammatory molecules in DED to provide the clinician with an appreciation for the ways in which these factors might be manipulated in DED management.

Download full-text PDF

Source
http://dx.doi.org/10.1111/cxo.12849DOI Listing

Publication Analysis

Top Keywords

ocular surface
16
role inflammation
8
dry eye
8
eye disease
8
immune response
8
ded
5
molecular evidence
4
evidence role
4
inflammation dry
4
disease
4

Similar Publications

Prcis: Preservative-free omidenepag isopropyl (OMDI) 0.002% ophthalmic solution and OMDI 0.002% ophthalmic solution preserved with benzalkonium chloride were bioequivalent in lowering intraocular pressure after 4 weeks' treatment in patients with primary open-angle glaucoma or ocular hypertension.

View Article and Find Full Text PDF

Background: Dry eye syndrome (DES) has become a significant public health issue, impacting quality of life. Meibomian Gland Dysfunction (MGD) is a primary contributor to DES, and its etiology includes diverse factors. Given the potential for drug-induced MGD, comprehensive investigation into this association is crucial.

View Article and Find Full Text PDF

Hyperglycemia causes differential change in macrophage population in the lacrimal gland, conjunctiva and cornea.

Front Immunol

January 2025

Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Chapman University, Irvine, CA, United States.

Background: Due to its location, the ocular surface is exposed to environmental microbes. Innate immune cells including macrophages are first line defense against infections. exposure to high glucose as well as diabetes-associated hyperglycemia has been shown to affect innate immune cell function and population.

View Article and Find Full Text PDF

DMEK Surgical Strategy in Aphakic and Vitrectomized Eyes.

Eur J Ophthalmol

January 2025

Cornea and Refractive Surgery Unit, Instituto de Microcirugía Ocular (IMO), Barcelona, 08035, Spain.

Purpose: After 15 years of accumulated experience in the Descemet Membrane Endothelial Keratoplasty (DMEK) technique, this surgical method has demonstrated a high reproducibility and success rate. However, certain ocular conditions such as aphakia and previously vitrectomized eyes remain challenging. We describe a novel technique designed to improve surgical time and postoperative outcomes in these specific scenarios.

View Article and Find Full Text PDF

Combination of Apigenin and Melatonin with nanostructured lipid carriers as anti-inflammatory ocular treatment.

Int J Pharm

December 2024

Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, University of Barcelona, 08028 Barcelona, Spain; Institute of Nanoscience and Nanotechnology (IN(2)UB), University of Barcelona, 08028 Barcelona, Spain. Electronic address:

Ocular inflammation is a complex pathology with limited treatment options. While traditional therapies have side effects, novel approaches, such as natural compounds like Apigenin (APG) and Melatonin (MEL) offer promising solutions. APG and MEL, in combination with nanostructured lipid carriers (NLC), may provide a synergistic effect in treating ocular inflammation, potentially improving patient outcomes and reducing adverse effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!